A Proteomic Map of the Hallmarks of Aging

Key Takeaways

• Single‑cell proteome atlas maps aging hallmarks in yeast
• Over 90% of yeast hallmark proteins have human ortholog changes
• Nucleolar ribosome biogenesis disruption appears early in aging
• Proteostasis loss and mitochondrial dysfunction precede other hallmarks
• Spatial protein relocalization links multiple aging hallmarks

Summary

Researchers created a single‑cell, subcellular proteome atlas of replicative aging in yeast, revealing hundreds of previously unknown protein changes tied to the classic hallmarks of aging. Spatial analysis showed that hallmark phenotypes often manifest as compartment‑specific relocalization and aggregation. Over 91% of the identified yeast proteins have human orthologs that also shift during aging, underscoring strong cross‑species conservation. Temporal profiling suggests that nucleolar ribosome‑biogenesis disruption, proteostasis decline, and mitochondrial dysfunction arise before other hallmarks, outlining a hierarchical cascade of cellular failure.

Pulse Analysis

Aging research has long relied on the nine hallmarks framework, yet the spatial context of protein changes remained elusive. Leveraging yeast’s replicative lifespan, the new study applied single‑cell proteomics to chart protein abundance, localization, and aggregation across subcellular compartments. This high‑resolution map captures how genomic instability, epigenetic drift, loss of proteostasis, and mitochondrial decline intersect within the cell, providing a granular view that bridges molecular biology and systems aging.

The investigators identified hundreds of hallmark‑linked proteins whose expression patterns shift with age, and strikingly, 91.6% of these have human orthologs that exhibit similar alterations in aging tissues. Temporal ordering revealed that disruptions in nucleolar ribosome biogenesis, followed by proteostasis collapse and mitochondrial dysfunction, consistently precede downstream hallmarks such as senescence and inflammation. This suggests a hierarchical cascade where early spatial disorganization sets the stage for broader cellular decline, offering a predictive framework for pinpointing the most impactful intervention points.

For biotech and pharmaceutical stakeholders, these insights translate into actionable targets. Early‑stage proteins governing nucleolar integrity, protein quality control, and mitochondrial health become prime candidates for drug development, diagnostic biomarkers, or gene‑editing strategies. Moreover, the cross‑species conservation validates yeast as a rapid screening platform, accelerating preclinical pipelines. As the field moves toward precision geroscience, integrating spatial proteomics with multi‑omics and AI‑driven modeling will likely refine the hierarchy further, paving the way for therapies that address aging at its root rather than treating downstream symptoms.